Latest Lenvatinib Stories
Tokyo, Sept 17, 2014 - (JCN Newswire) - Eisai Co., Ltd.
Phase 3 Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival in Radioiodine-Refractory Differentiated Thyroid Cancer
WOODCLIFF LAKE, N.J., Feb. 2, 2014 /PRNewswire/ -- Eisai Inc. announced today that the Phase 3 SELECT trial (Study 303) of investigational agent lenvatinib met its primary endpoint.
Word of the Day
- The act of sweetening by admixture of some saccharine substance.
The word 'edulcoration' comes from a Latin word meaning 'making sweet'.